Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tetrabenazine
Drug ID BADD_D02175
Description A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Indications and Usage Treatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
Marketing Status approved; investigational
ATC Code N07XX06
DrugBank ID DB04844
KEGG ID D08575
MeSH ID D013747
PubChem ID 6018
TTD Drug ID D09PJX
NDC Product Code 51224-425; 67386-421; 68180-409; 63827-1013; 65977-0085; 47335-277; 51407-481; 27241-177; 60505-3882; 65085-0064; 27241-176; 47335-179; 69452-117; 70436-102; 43598-395; 60505-3883; 70436-101; 57821-010; 51407-480; 68682-422; 31722-821; 43598-394; 51224-426; 69452-118; 69766-076; 31722-822; 67386-422; 42973-179; 68180-408; 68682-421; 64330-066; 64567-0025; 65015-831
UNII Z9O08YRN8O
Synonyms Tetrabenazine | Nitoman | Xenazine
Chemical Information
Molecular Formula C19H27NO3
CAS Registry Number 718635-93-9
SMILES CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mood altered19.04.02.0070.001830%Not Available
Mood swings19.04.03.0010.002100%Not Available
Movement disorder17.01.02.0100.005653%Not Available
Muscle injury15.05.07.001; 12.01.07.002--Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.004091%Not Available
Muscle twitching15.05.03.0050.001184%Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.0010.001077%Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.0030.002369%Not Available
Neuroleptic malignant syndrome15.05.04.015; 12.03.01.003; 08.05.01.005; 17.05.02.0030.000808%Not Available
Obsessive-compulsive disorder19.06.05.002--Not Available
Oculogyric crisis06.05.02.002; 17.01.03.0020.000538%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.001--Not Available
Paranoia19.05.01.0050.000808%Not Available
Parkinsonism17.01.05.0030.003069%Not Available
Photophobia17.17.02.006; 06.01.01.004--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Rash23.03.13.001--Not Available
Respiratory arrest22.02.01.0090.001077%Not Available
Respiratory disorder22.02.07.0020.000538%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001077%
Restlessness19.11.02.002; 17.02.05.0210.004199%
Rhabdomyolysis15.05.05.0020.000808%
Salivary hypersecretion07.06.01.0090.001346%Not Available
Sedation17.02.04.0050.002907%Not Available
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.0060.019488%
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages